Leadership Team
Kiyotaka Fujii
President, Global Healthcare,
Konica Minolta & Chairman,
Ambry Genetics and Invicro
Kiyotaka Fujii
President, Global Healthcare, Konica Minolta & Chairman, Ambry Genetics
Kiyotaka Fujii leads Konica Minolta’s global healthcare business, which focuses on the advancement of Precision Medicine and Medical Diagnostics. Fujii is also Chairman of Ambry Genetics and Invicro, a biomarker imaging CRO based in Boston.
Fujii’s extensive business career ranges from medical services, information technology, and consumer products to investment banking. Fujii has held several Japan CEO positions with top global companies since 1997, including SAP, Louis Vuitton, Cadence Design Systems and Quintiles Transnational. From 2012 to 2015, he served at Olympus as the first independent board member to re-build its governance and businesses.
From 1986 to 1993, Fujii held the role as the first Japanese M&A investment banker in New York with Credit Suisse First Boston and Goldman Sachs. Fujii began his career with McKinsey as the first hire from a Japanese University.
As the author of "Global Mind," a top-selling Japanese business book, Fujii is often consulted for his perspective as a global business leader in Japan by the government and news media.
Fujii received an MBA from the Harvard Business School in 1986 and a B.A. in Law from the University of Tokyo in 1981.
Aaron Elliott, PhD
CEO, Konica Minolta Precision Medicine
Aaron Elliott, PH.D.
Chief Executive Officer, Konica Minolta Precision Medicine
Dr. Aaron Elliott is responsible for driving execution across all Konica Minolta Precision
Medicine (KMPM) business units, which include Ambry Genetics, Invicro and KMPM-Japan.
Prior to his role as CEO of KMPM, Dr. Elliott was at Ambry Genetics leading the company
through 13 years of trailblazing milestones. He joined Ambry in 2008 in the research and
development department working closely on the development of comprehensive molecular
diagnostic tests. An innovator in complex genetic testing, Dr. Elliott has been involved in
the conception and implementation of many of the diagnostic industry first to market tests
and technologies including the first commercial NGS assay, CLIA/CAP Exome test and
hereditary cancer panels among others. Dr. Elliott and the Ambry team were instrumental in
mounting a creative defense in the groundbreaking University of Utah Research Foundation, et
al., v. Ambry Genetics Corporation case which ended the monopoly of BRCA testing in the
United States.
Dr. Elliott has helped guide the company through extreme periods of growth, including the
acquisition by Konica Minolta. Over the years he held many leadership positions at Ambry,
including Director of Genomic Services, Chief Operating Officer, Chief Scientific
Officer, and and Chief Executive Officer.
Dr. Elliott began his career as a Postdoctoral Fellow at the Novartis Institute of
Functional Genomics in San Diego, where he conducted research on potential drug targets for
chemotherapeutic resistance and tumor formation. As part of this research, Dr. Elliott
helped in identifying the first mitochondrial ABC transporter in cancer cells, which are
responsible for multi-drug resistance in many solid tumors.
A graduate of Franklin and Marshall College, Dr. Elliott conducted his Ph.D. Genetics
training at Thomas Jefferson University and The Johns Hopkins University School of Medicine.
Tsuyoshi Mitsuhashi
President, Konica Minolta Precision Medicine Japan, Inc.
Tsuyoshi Mitsuhashi
President, Konica Minolta Precision Medicine Japan, Inc.
Tsuyoshi Mitsuhashi was appointed President of Konica Minolta Precision Medicine Japan, Inc. in October 2019. He joined Konishiroku Photo Industry Co., Ltd., which later became Konica Corporation, in 1987. After engaging in the development of medical X-ray film and dry film, he led the development of an Ultrasound system, which was a new business field for the company.
Having served as General Manager of the Healthcare Business Planning Division of Konica Minolta, Inc. (Konica Minolta), Mitsuhashi played a pivotal role in the launch of the Precision Medicine Business in 2017, with a focus on corporate planning and M&A, among other areas.
Taking advantage of his many years of knowledge and experience in the fields of chemistry, imaging, and medical care, he has been working on technical developments and business growth based on Konica Minolta's strengths and innovation in precision medicine and is also in charge of the Precision Medicine Business Unit at Konica Minolta.
Aaron Elliott, PH.D.
Chief Executive Officer, Konica Minolta Precision Medicine
Dr. Aaron Elliott is responsible for driving execution across all Konica Minolta Precision
Medicine (KMPM) business units, which include Ambry Genetics, Invicro and KMPM-Japan.
Prior to his role as CEO of KMPM, Dr. Elliott was at Ambry Genetics leading the company
through 13 years of trailblazing milestones. He joined Ambry in 2008 in the research and
development department working closely on the development of comprehensive molecular
diagnostic tests. An innovator in complex genetic testing, Dr. Elliott has been involved in
the conception and implementation of many of the diagnostic industry first to market tests
and technologies including the first commercial NGS assay, CLIA/CAP Exome test and
hereditary cancer panels among others. Dr. Elliott and the Ambry team were instrumental in
mounting a creative defense in the groundbreaking University of Utah Research Foundation, et
al., v. Ambry Genetics Corporation case which ended the monopoly of BRCA testing in the
United States.
Dr. Elliott has helped guide the company through extreme periods of growth, including the
acquisition by Konica Minolta. Over the years he held many leadership positions at Ambry,
including Director of Genomic Services, Chief Operating Officer, Chief Scientific
Officer, and and Chief Executive Officer.
Dr. Elliott began his career as a Postdoctoral Fellow at the Novartis Institute of
Functional Genomics in San Diego, where he conducted research on potential drug targets for
chemotherapeutic resistance and tumor formation. As part of this research, Dr. Elliott
helped in identifying the first mitochondrial ABC transporter in cancer cells, which are
responsible for multi-drug resistance in many solid tumors.
A graduate of Franklin and Marshall College, Dr. Elliott conducted his Ph.D. Genetics
training at Thomas Jefferson University and The Johns Hopkins University School of Medicine.
Kiyotaka Fujii
President, Global Healthcare, Konica Minolta & Chairman, Ambry Genetics
Kiyotaka Fujii leads Konica Minolta’s global healthcare business, which focuses on the advancement of Precision Medicine and Medical Diagnostics. Fujii is also Chairman of Ambry Genetics and Invicro, a biomarker imaging CRO based in Boston.
Fujii’s extensive business career ranges from medical services, information technology, and consumer products to investment banking. Fujii has held several Japan CEO positions with top global companies since 1997, including SAP, Louis Vuitton, Cadence Design Systems and Quintiles Transnational. From 2012 to 2015, he served at Olympus as the first independent board member to re-build its governance and businesses.
From 1986 to 1993, Fujii held the role as the first Japanese M&A investment banker in New York with Credit Suisse First Boston and Goldman Sachs. Fujii began his career with McKinsey as the first hire from a Japanese University.
As the author of "Global Mind," a top-selling Japanese business book, Fujii is often consulted for his perspective as a global business leader in Japan by the government and news media.
Fujii received an MBA from the Harvard Business School in 1986 and a B.A. in Law from the University of Tokyo in 1981.
Tom Schoenherr
CEO, Ambry Genetics
Tom Schoenherr
Chief Executive Officer, Ambry Genetics
Tom Schoenherr is responsible for the strategic, financial and operational leadership of the
organization.
Tom joined Ambry in 2017 as Chief Commercial Officer and was responsible for the execution of Ambry’s
go-to-market strategy and overseeing all commercial functions including service, support, sales,
marketing, business development, managed care and genetic specialists. Prior to Ambry, Tom spent more
than 20 years in leadership positions in the molecular diagnostics space, most recently as the CCO of
Omada Health where he was responsible for driving business growth and increasing market share. He also
served in similar roles at Counsyl, Quest Diagnostics, Siemens Healthcare and Abbott Diagnostics. Tom
earned his BS from Michigan State University and completed his Executive Business Development Program
from the University of Notre Dame.
Matthew Silva, PhD
CEO, Invicro
Matthew Silva, PhD
CEO, Invicro
Dr. Matthew Silva serves as Chief Executive Officer of Invicro, backed by 20 years of diverse technical and
management experience, and is responsible for the strategic direction and tactical performance of the business. Dr.
Silva has been with Invicro for 7 years in various executive positions, including leading Scientific and Medical
Services. Prior to Invicro, Dr. Silva was Senior Director of Translational Biology at Vertex Pharmaceuticals, where
he ran the in vivo imaging and histopathology groups supporting discovery and clinical. Previously, Dr. Silva led
groups at Amgen, Millennium and Takeda Pharmaceuticals. He holds a Ph.D. and M.S. in Biomedical Engineering from
Worcester Polytechnic Institute and a B.S. in Biomedical Engineering from Boston University.
Ken Bloom, MD
CMO, Advanced Pathology & Genomic Services
Dr. Ken Bloom
CMO, Advanced Pathology & Genomic Services
Dr. Bloom brings more than 30 years of clinical and business experience in pathology, oncology, telemedicine, and bioinformatics. His role will be to help expand, strengthen and commercialize the full-suite of precision medicine capabilities offered within the pathology and genomics markets for Invicro and Ambry Genetics.
Previously, Dr. Bloom was President and Head of Oncology & Immunotherapy for Human Longevity Inc., where his team developed and commercialized an industry leading cancer exome product and commercialized a technique for validating neoantigens predicted from sequencing. Dr. Bloom was also instrumental to the business strategy that evolved Clarient from a start-up to the acquisition by GE Healthcare.
Prior to his industry experience, Dr. Bloom spent 15 years within the academic field holding various appointed positions including Director of Laboratory Operations and Chief Information Officer of the Rush Cancer Institute, Clinical Professor of Pathology at University of Southern California, Keck School of Medicine; and Associate Professor of Pathology at Rush Medical College. Dr. Bloom received his MD from Rush Medical College and his BA from Grinnell College.
Matthew Silva, PhD
CEO, Invicro
Dr. Matthew Silva serves as Chief Executive Officer of Invicro, backed by 20 years of diverse technical and
management experience, and is responsible for the strategic direction and tactical performance of the business. Dr.
Silva has been with Invicro for 7 years in various executive positions, including leading Scientific and Medical
Services. Prior to Invicro, Dr. Silva was Senior Director of Translational Biology at Vertex Pharmaceuticals, where
he ran the in vivo imaging and histopathology groups supporting discovery and clinical. Previously, Dr. Silva led
groups at Amgen, Millennium and Takeda Pharmaceuticals. He holds a Ph.D. and M.S. in Biomedical Engineering from
Worcester Polytechnic Institute and a B.S. in Biomedical Engineering from Boston University.
Tom Schoenherr
Chief Executive Officer, Ambry Genetics
Tom Schoenherr is responsible for the strategic, financial and operational leadership of the
organization.
Tom joined Ambry in 2017 as Chief Commercial Officer and was responsible for the execution of Ambry’s
go-to-market strategy and overseeing all commercial functions including service, support, sales,
marketing, business development, managed care and genetic specialists. Prior to Ambry, Tom spent more
than 20 years in leadership positions in the molecular diagnostics space, most recently as the CCO of
Omada Health where he was responsible for driving business growth and increasing market share. He also
served in similar roles at Counsyl, Quest Diagnostics, Siemens Healthcare and Abbott Diagnostics. Tom
earned his BS from Michigan State University and completed his Executive Business Development Program
from the University of Notre Dame.
Scientific Advisory Board Members
John Niederhuber, MD
President and CEO of the Genomics and Bioinformatics Research Institute
John Niederhuber, MD
President and CEO of the Genomics and Bioinformatics Research Institute
Previously, Dr. Niederhuber served as the Director of the National Cancer Institute, National Institutes of Health, and currently serves as the Executive Vice President and CEO of Inova Translational Medicine Institute (ITMI) and is the newly appointed President and CEO of the Genomics and Bioinformatics Research Institute (GBRI), a new research institute jointly funded by the University of Virginia and the Inova Health System. He is also a Professor of Public Health Sciences at the University of Virginia School of Medicine, Adjunct Professor of Oncology and Surgery at Johns Hopkins University School of Medicine, and Deputy Director of the Johns Hopkins Clinical Research Network.
Dr. Niederhuber has dedicated his highly successful career to the study and treatment of cancer. As a child growing up in a small steel mill town in Ohio, he was inspired by the local doctor who often made house calls on his way home, understanding then the value of personalized patient care. Dr. Niederhuber passionately believes that the precise blending of oncology, radiation, imaging and pathology offers the best solutions for complex diseases like cancer, by matching more patients to more effective therapies.
Judy E. Garber, MD, MPH
Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute
Dr. Judy E. Garber
Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute
Dr. Garber is the Susan F. Smith Chair and Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. She conducts research in clinical cancer genetics, with a special focus in the genetics of breast cancer. She has played a major role in the development of national guidelines in cancer genetics. Dr. Garber is also a leader in research into the characteristics and treatment of triple negative or basal-like breast cancer, the most common form in women with BRCA1 mutations and an expert in Li-Fraumeni Syndrome. Her translational research focuses on the evaluation of novel agents targeting DNA repair defects in breast cancer, including PARP inhibitors for treatment and prevention of breast cancer and other BRCA-associated cancers.
Dr. Garber is a past president of the American Association for Cancer Research (AACR). She serves on the National Cancer Advisory Board of the National Cancer Institute and was elected into the National Academy of Medicine in 2013. She also serves as the Co-Scientific Director of the Breast Cancer Research Foundation and past chair of the Breast Cancer Research Foundation Scientific Advisory Board. She is an ASCO Statesman and a Fellow of the AACR Academy.
David Rimm, MD, PhD
Professor, Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine
John Niederhuber, MD
President and CEO of the Genomics and Bioinformatics Research Institute
Previously, Dr. Niederhuber served as the Director of the National Cancer Institute, National Institutes of Health, and currently serves as the Executive Vice President and CEO of Inova Translational Medicine Institute (ITMI) and is the newly appointed President and CEO of the Genomics and Bioinformatics Research Institute (GBRI), a new research institute jointly funded by the University of Virginia and the Inova Health System. He is also a Professor of Public Health Sciences at the University of Virginia School of Medicine, Adjunct Professor of Oncology and Surgery at Johns Hopkins University School of Medicine, and Deputy Director of the Johns Hopkins Clinical Research Network.
Dr. Niederhuber has dedicated his highly successful career to the study and treatment of cancer. As a child growing up in a small steel mill town in Ohio, he was inspired by the local doctor who often made house calls on his way home, understanding then the value of personalized patient care. Dr. Niederhuber passionately believes that the precise blending of oncology, radiation, imaging and pathology offers the best solutions for complex diseases like cancer, by matching more patients to more effective therapies.
Dr. Judy E. Garber
Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute
Dr. Garber is the Susan F. Smith Chair and Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. She conducts research in clinical cancer genetics, with a special focus in the genetics of breast cancer. She has played a major role in the development of national guidelines in cancer genetics. Dr. Garber is also a leader in research into the characteristics and treatment of triple negative or basal-like breast cancer, the most common form in women with BRCA1 mutations and an expert in Li-Fraumeni Syndrome. Her translational research focuses on the evaluation of novel agents targeting DNA repair defects in breast cancer, including PARP inhibitors for treatment and prevention of breast cancer and other BRCA-associated cancers.
Dr. Garber is a past president of the American Association for Cancer Research (AACR). She serves on the National Cancer Advisory Board of the National Cancer Institute and was elected into the National Academy of Medicine in 2013. She also serves as the Co-Scientific Director of the Breast Cancer Research Foundation and past chair of the Breast Cancer Research Foundation Scientific Advisory Board. She is an ASCO Statesman and a Fellow of the AACR Academy.
David Rimm, MD, PhD
Professor, Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine
Dr. David Rimm is a Professor in the Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine. He is the Director of Yale Pathology Tissue Services. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is boarded in Anatomic and Cytopatholgy. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, with projects related to predicting response to both targeted and immune- therapy in cancer and standardization of those assays for CLIA labs. His lab is involved in testing new high-plex methods including imaging mass cytometry (Fluidigm) and digital spatial profiling (NanoString) He also has supported projects related to rapid, low cost diagnostic tests and direct tissue imaging. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He also serves on the CAP Immunohistochemistry committee and multiple scientific advisory boards for biotech and pharma. He is an author of over 350 peer-reviewed papers and 8 patents.
Geoffrey Ginsburg, MD, PhD
Founding Director, Center for Applied Genomics & Precision Medicine at the Duke University Medical Center
Geoffrey S Ginsburg, MD, PhD
Founding Director, Center for Applied Genomics & Precision Medicine at the Duke University Medical Center
Dr. Ginsburg is the founding director for the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center and for MEDx, a partnership between the Schools of Medicine and Engineering to spark and translate innovation. His research addresses the challenges for translating genomic information into medical practice and the integration of precision medicine into healthcare. In 2017 he received Duke’s Translational Research Mentorship Award.
He is a member of the Advisory Council to the Director of NIH and is co-chair of the National Academies Roundtable on Genomic and Precision Health and is founder and president of the Global Genomic Medicine Collaborative, a not for profit organization aimed creating international partnerships to advance the implementation of precision medicine. He has recently served as a member of the Board of External Experts for the NHLBI, the advisory council for the National Center for Accelerating Translational Science, the chair of the review for Genome Canada’s Large Scale Applied Research Competition in Genomics and Precision Medicine, and the World Economic Forum’s Global Agenda Council on the Future of the Health Sector. He was previously Vice President of Molecular Medicine at Millennium Pharmaceuticals, Inc and a faculty member at Harvard Medical School.
Giovanni Parmigiani, PhD
Associate Director for Population Sciences of the Multi-Institutional Dana-Farber/Harvard Cancer Center
Giovanni Parmigiani
Associate Director for Population Sciences of the Multi-Institutional Dana-Farber/Harvard Cancer Center
Giovanni Parmigiani's research investigates statistical principles and tools, often with a focus on understanding cancer data. For example, he is currently interested in addressing the challenges of cross-study replication of predictions, by constructing predictors that learn replicability from being trained on multiple studies at once. He also has a long term interest in helping families who are particularly susceptible to inherited cancer understand their risk and make informed decisions. He uses Bayesian modeling and machine learning concepts to predict who is at risk of carrying genetic variants, and to integrate literature-based and other information about the effects of mutations. Visit the BayesMendel page to find out more about this line of investigation.
Throughout his research activities, his broad goals are to find innovative ways to use data science and data technologies to fuel cancer prevention and early detection and, methodologically, to increase the rigor end efficiency with which we leverage the vast and complex information generated in today’s cancer research. He strives to foster the use of data sciences as a common thread to facilitate interactions between fields and academic cultures, and has a passion for mentoring and training young(er) scientists in interdisciplinary settings.
Since joining Harvard in 2009 he has taken on several leadership roles: he is the Associate Director for Population Sciences of the multi-institutional Dana-Farber / Harvard Cancer Center (DF/HCC), and is the director of the postdoctoral training grant in Quantitative Sciences for Cancer Research at the Harvard T.H. Chan School of Public Health, where he is a Professor. He has been the Chairman of the Department of Biostatistics & Computational Biology at Dana-Farber Cancer Institute from 2009 to 2018, and the Leader of the DF/HCC Biostatistics and Computational Biology Program (now Cancer Data Sciences Program) from 2009 to 2015.
Howard I. Scher, MD
Co-Chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center
Geoffrey S Ginsburg, MD, PhD
Founding Director, Center for Applied Genomics & Precision Medicine at the Duke University Medical Center
Dr. Ginsburg is the founding director for the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center and for MEDx, a partnership between the Schools of Medicine and Engineering to spark and translate innovation. His research addresses the challenges for translating genomic information into medical practice and the integration of precision medicine into healthcare. In 2017 he received Duke’s Translational Research Mentorship Award.
He is a member of the Advisory Council to the Director of NIH and is co-chair of the National Academies Roundtable on Genomic and Precision Health and is founder and president of the Global Genomic Medicine Collaborative, a not for profit organization aimed creating international partnerships to advance the implementation of precision medicine. He has recently served as a member of the Board of External Experts for the NHLBI, the advisory council for the National Center for Accelerating Translational Science, the chair of the review for Genome Canada’s Large Scale Applied Research Competition in Genomics and Precision Medicine, and the World Economic Forum’s Global Agenda Council on the Future of the Health Sector. He was previously Vice President of Molecular Medicine at Millennium Pharmaceuticals, Inc and a faculty member at Harvard Medical School.
Giovanni Parmigiani
Associate Director for Population Sciences of the Multi-Institutional Dana-Farber/Harvard Cancer Center
Giovanni Parmigiani's research investigates statistical principles and tools, often with a focus on understanding cancer data. For example, he is currently interested in addressing the challenges of cross-study replication of predictions, by constructing predictors that learn replicability from being trained on multiple studies at once. He also has a long term interest in helping families who are particularly susceptible to inherited cancer understand their risk and make informed decisions. He uses Bayesian modeling and machine learning concepts to predict who is at risk of carrying genetic variants, and to integrate literature-based and other information about the effects of mutations. Visit the BayesMendel page to find out more about this line of investigation.
Throughout his research activities, his broad goals are to find innovative ways to use data science and data technologies to fuel cancer prevention and early detection and, methodologically, to increase the rigor end efficiency with which we leverage the vast and complex information generated in today’s cancer research. He strives to foster the use of data sciences as a common thread to facilitate interactions between fields and academic cultures, and has a passion for mentoring and training young(er) scientists in interdisciplinary settings.
Since joining Harvard in 2009 he has taken on several leadership roles: he is the Associate Director for Population Sciences of the multi-institutional Dana-Farber / Harvard Cancer Center (DF/HCC), and is the director of the postdoctoral training grant in Quantitative Sciences for Cancer Research at the Harvard T.H. Chan School of Public Health, where he is a Professor. He has been the Chairman of the Department of Biostatistics & Computational Biology at Dana-Farber Cancer Institute from 2009 to 2018, and the Leader of the DF/HCC Biostatistics and Computational Biology Program (now Cancer Data Sciences Program) from 2009 to 2015.
Howard I. Scher
Co-Chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative
Co-Chair, Center for Mechanism Based Therapy; Head of the Biomarker Development Initiative; Member and Attending Physician, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher’s research is focused on the codevelopment of targeted therapies and biomarkers such as circulating tumor cells (CTCs) which can be used to guide treatment selection for the individual patient and improve the way drugs are evaluated in the clinic, accelerating regulatory approvals. Accordingly, he has led international efforts to standardize the design and analysis of phase II prostate cancer trials (PCWG2, PCWG3) and helped elucidate key molecular and genetic features of prostate cancer, translating these insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide which are now FDA approved. Dr. Scher serves as the principal investigator of the NIH Specialized Program of Research Excellence (SPORE) in Prostate Cancer at MSKCC and the Department of Defense-sponsored Prostate Cancer Clinical Trials Consortium (PCCTC), and has received the 2015 AACR Team Science Award for his multidisciplinary work developing AR inhibitors. Most recently Dr. Scher was elected to the Association of American Physicians and named a Fellow of the American Society of Clinical Oncology (ASCO).
